Oral peptide delivery research must address enzymatic degradation, low epithelial permeability, variable gastrointestinal conditions and the gap between uptake and useful exposure.
The gastrointestinal barrier stack
A peptide may encounter low pH, proteases, mucus, changing fluid volume and epithelial tight junctions before any absorbed fraction reaches circulation. Improving one barrier does not guarantee that the remaining steps become nonlimiting.
Common strategy families
Protective formulations, enzyme inhibitors, permeation enhancers, lipid systems, nanoparticles and molecular modification address different parts of the barrier stack. Each strategy also introduces its own stability, variability and safety questions.
Evidence across model scales
Release and stability tests, cell models, intestinal tissues and in vivo studies provide progressively different information. Model-specific limitations should be reported explicitly, especially when translating a high local signal into an absorption claim.
